The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 3, 2014, Pages 380-389

  Kamal, M A ^a   Acosta, E P ^b   Kimberlin, D W ^b   Gibiansky, L ^c   Jester, P ^b   Niranjan, V ^d   Rath, B ^e   Clinch, B ^f   Sanchez P J ^g   Ampofo, K ^h   Whitley, R ^b   Rayner, C R ^i,j  

^a Roche Pharma Research and Early Development Roche Innovation Center New York Roche TCRC Inc   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c QuantPharm LLC 49 Flints Grove Drive   (United States)

^d RxMD   (India)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ D3 Medicine LLC   (United States)

^j MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ABSORPTION; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; INFANT DISEASE; INFLUENZA; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; VIRAL CLEARANCE;

ADMINISTRATION, ORAL; AGE FACTORS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BODY WEIGHT; CARBOXYLIC ACIDS; COMPUTER SIMULATION; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; LINEAR MODELS; MALE; MODELS, BIOLOGICAL; OSELTAMIVIR;

EID: 84907864513     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.120     Document Type: Article

References (39)

1. World Health Organization. Wkly Epidemiol. Rec. 80, 279-287 (2005).
2. Glezen, W.P., Taber, L.H., Frank, A.L., Gruber, W.C. & Piedra, P.A. Influenza virus infections in infants. Pediatr. Infect. Dis. J. 16, 1065-1068 (1997).
3. Kliegman, R.M., Behrman, R.E., Jenson, H.B. & Stanton, B.F. Nelson Textbook of Pediatrics, 18th edn (Saunders, Philadelphia, PA, 2007).
4. Zaman, K. et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl. J. Med. 359, 1555-1564 (2008).
5. Rohner, G.B. et al. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenzaspecific antibodies to the newborn. Pediatr. Infect. Dis. J. 32, 1374-1380 (2013).
6. Omer, S.B. et al. Combined effects of antenatal receipt of influenza vaccine by mothers and pneumococcal conjugate vaccine receipt by infants: Results from a randomized, blinded, controlled trial. J. Infect. Dis. 207, 1144-1147 (2013).
7. Kimberlin, D.W. et al.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir pharmacokinetics, dosing, and resistance among children aged 2 years with influenza J. Infect. Dis. 207 709-720 2013
8. Rath, B. et al. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses. Pediatr. Infect. Dis. J. 31, 899-905 (2012).
9. Tamiflu Summary of Product Characteristics (SmPC). (2013).
10. Tamiflu Prescribing Information (PI). (2013). http://www.accessdata.fda. gov/scripts/ cder/drugsat.fda/index.cfm?fuseaction=Search.Search-Drug-Name
11. Rayner, C.R. et al. The pharmacokinetics and safety of oseltamivir in infants 1 year with influenza XIV International Symposium on Respiratory Viral Infections, Istanbul, Turkey, 23-26 March 2012.
12. Rath B.A et al. A prospective, open-label study of the pharmacokinetics, safety and pharmacodynamics of oseltamivir in infants
13. Oo, C. et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr. Drugs 3, 229-236 (2001).
14. Treanor, J.J. et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283, 1016-1024 (2000).
15. Nicholson, K.G. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355, 1845-1850 (2000).
16. He, G., Massarella, J. & Ward, P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37, 471-484 (1999).
17. Rayner, C.R. et al. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob. Agents Chemother. 57, 3478-3487 (2013).
18. Smith, J.R., Rayner, C.R., Donner, B., Wollenhaupt, M., Klumpp, K. & Dutkowski, R. Oseltamivir in seasonal, pandemic, and avian influenza: A comprehensive review of 10-years clinical experience. Adv. Ther. 28, 927-959 (2011).
19. Yang, D., Pearce, R.E., Wang, X., Gaedigk, R., Wan, Y.J. & Yan, B. Human carboxylesterases HCE1 and HCE2: Ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol. 77, 238-247 (2009).
20. Standing, J.F. et al. Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. Antimicrob. Agents Chemother. 56, 3833-3840 (2012).
21. Acosta, E.P. & Kimberlin, D.W. Determination of appropriate dosing of influenza drugs in pediatric patients. Clin. Pharmacol. Ther. 88, 704-707 (2010).
22. Shi, D., Yang, D., Prinssen, E.P., Davies, B.E. & Yan, B. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. J. Infect. Dis. 203, 937-942 (2011).
23. Parrott, N. et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet. 50, 613-623 (2011).
24. Rayner, C.R., Chanu, P., Gieschke, R., Boak, L.M. & Jonsson, E.N. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J. Clin. Pharmacol. 48, 935-947 (2008).
25. Acosta, E.P. et al.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202, 563-566 (2010).
26. McPherson, C., Warner, B., Hunstad, D.A., Elward, A. & Acosta, E.P. Oseltamivir dosing in premature infants. J. Infect. Dis. 206, 847-850 (2012).
27. Anderson, B.J. & Holford, N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008).
28. Holford, N.H. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30, 329-332 (1996).
29. Meibohm, B., Läer, S., Panetta, J.C. & Barrett, J.S. Population pharmacokinetic studies in pediatrics: Issues in design and analysis. AAPS J. 7, E475-E487 (2005).
30. Harrell, F.E. Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis. (Springer-Verlag, New York, 2001).
31. Gastonguay, M.R. A full model estimation approach for covariate effects: Inference based on clinical importance and estimation precision. AAPS J. 66(suppl. 1), W4354 (2004).
32. Gastonguay, M.R. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: A review of methodology and 42 case studies. PAGE 20. Abstr. 2229. (2011).
33. Efron, B. Missing data, imputation, and the bootstrap. J. Am. Stat. Assoc. 89, 463-479 (1994).
34. Parke, J., Holford, N.H. & Charles, B.G. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59, 19-29 (1999).
35. Wang, D.D. & Zhang, S. Standardized visual predictive check-how and when to use it in model evaluation. Population Approach Group Europe (PAGE)
36. Abstr. 1501, Glasgow, Scotland, 2013.
37. Oo, C. et al. An open label study of the pharmacokinetics of oseltamivir (Ro 64-0796) in children aged 0-5 years old after a single dose. Eur. J. Clin. Pharmacol. 59, 411-415 (2003).
38. Hayden, F. et al. A randomized, open-label, parallel group study of oseltamivir used for management of influenza in households. J. Infect. Dis. 184, 440-449 (2004).
39. Dutkowski, R. et al. A randomized, double blind, parallel group, placebo controlled study of the effect of oseltamivir on ECG intervals in healthy subjects. Int. J. Antimicrob. Agents. 35, 461-467 (2010).